Apr 21, 2025 | Biosimilars, Cost Savings, Drug costs, Rx Costs, Savings, Stelara
Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by...
Mar 11, 2025 | Drug costs, GLP-1s, Health care costs, Ozempic, Pharmacy, Rx Costs, Wegovy, Weight loss, Weight loss drugs, Zepbound
The end of shortages on Ozempic, Wegovy, and other semaglutide injections could place added pressure on self-funded health plans to cover the costs of the high-priced medications. On February 21, the FDA confirmed that the supply of GLP-1 drugs used to treat obesity...
Feb 24, 2025 | Benefits preservation, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
High-cost specialty drugs can make up more than 60% of a health plan’s pharmacy costs. MedBen Rx’s benefit preservation program is designed to make certain that members have continued access to medications while reducing specialty drug spend to the...
Feb 10, 2025 | Chronic conditions, Cost Savings, Drug costs, Flexible spending accounts (FSAs), Health care costs, MedBen Rx, Pharmacogenomics, Rx Costs, Savings
Now available through MedBen Rx, pharmacogenomic testing is transforming health care through safer and more effective personalized medicine. Determining how genes affect a person’s response to drugs not only improves patient outcomes, but it also helps control...
Feb 7, 2025 | Employee benefits, High-cost claims, Hospitals, Rx Costs, Survey
In a recent “Pulse of the Purchaser” employer survey, nearly three-quarters (74%) of respondents indicated that rising health care costs might force them to reconsider wage or salary increases. The same percentage also believe that rising costs will compel...
Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
